PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis

Antonio Rossi; Vincenzo Di Noia; Anastasios Gkountakos; Ettore D'Argento; Giulia Sartori; Emanuele Vita; Sara Monteverdi; Fiorella Lombardo; Roberto Iacovelli; Luisa Carbognin; Isabella Sperduti; Michele Milella; Giampaolo Tortora; Emilio Bria; Sara Pilotto

doi:10.2217/imt-2018-0198

PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis

Antonio Rossi, Vincenzo Di Noia, Anastasios Gkountakos, Ettore D'Argento, Giulia Sartori, Emanuele Vita, Sara Monteverdi, Fiorella Lombardo, Roberto Iacovelli, Luisa Carbognin, Isabella Sperduti, Michele Milella, Giampaolo Tortora, Emilio Bria, Sara Pilotto

Istituto Regina Elena

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; pÂ =Â 0.001) and PFS (HR 0.61; pÂ

Original language	Italian
Pages (from-to)	921-930
Number of pages	10
Journal	Immunotherapy
Volume	11
Issue number	10
DOIs	https://doi.org/10.2217/imt-2018-0198
Publication status	Published - 2019

Access to Document

10.2217/imt-2018-0198

https://www.ncbi.nlm.nih.gov/pubmed/31155995

Cite this

Rossi, A., Noia, V. D., Gkountakos, A., D'Argento, E., Sartori, G., Vita, E., Monteverdi, S., Lombardo, F., Iacovelli, R., Carbognin, L., Sperduti, I., Milella, M., Tortora, G., Bria, E., & Pilotto, S. (2019). PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. Immunotherapy, 11(10), 921-930. https://doi.org/10.2217/imt-2018-0198

Rossi, A, Noia, VD, Gkountakos, A, D'Argento, E, Sartori, G, Vita, E, Monteverdi, S, Lombardo, F, Iacovelli, R, Carbognin, L, Sperduti, I, Milella, M, Tortora, G, Bria, E & Pilotto, S 2019, 'PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis', Immunotherapy, vol. 11, no. 10, pp. 921-930. https://doi.org/10.2217/imt-2018-0198

@article{0991dead6f4249d4a0e4483fd395fa2a,

title = "PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis",

abstract = "Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; p{\^A} ={\^A} 0.001) and PFS (HR 0.61; p{\^A} ",

keywords = "*NSCLC, *PD-1, *PD-L1, *atezolizumab, *first line, *immunotherapy, *meta-analysis, *nivolumab, *pembrolizumab",

author = "Antonio Rossi and Noia, {Vincenzo Di} and Anastasios Gkountakos and Ettore D'Argento and Giulia Sartori and Emanuele Vita and Sara Monteverdi and Fiorella Lombardo and Roberto Iacovelli and Luisa Carbognin and Isabella Sperduti and Michele Milella and Giampaolo Tortora and Emilio Bria and Sara Pilotto",

note = "J2: Immunotherapy M1 - Journal Article",

year = "2019",

doi = "10.2217/imt-2018-0198",

language = "Italian",

volume = "11",

pages = "921--930",

journal = "Immunotherapy",

issn = "1750-743X",

publisher = "Future Medicine Ltd.",

number = "10",

}

TY - JOUR

T1 - PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis

AU - Rossi, Antonio

AU - Noia, Vincenzo Di

AU - Gkountakos, Anastasios

AU - D'Argento, Ettore

AU - Sartori, Giulia

AU - Vita, Emanuele

AU - Monteverdi, Sara

AU - Lombardo, Fiorella

AU - Iacovelli, Roberto

AU - Carbognin, Luisa

AU - Sperduti, Isabella

AU - Milella, Michele

AU - Tortora, Giampaolo

AU - Bria, Emilio

AU - Pilotto, Sara

N1 - J2: Immunotherapy M1 - Journal Article

PY - 2019

Y1 - 2019

N2 - Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; pÂ =Â 0.001) and PFS (HR 0.61; pÂ

AB - Aim: With the final aim to explore the first-line treatment options for non-small-cell lung cancer (NSCLC) patients, we performed a systematic review and literature-based meta-analysis of available clinical trials exploring immunotherapy in combination versus standard histology-based chemotherapy. Materials & methods: We evaluated interactions according to type of treatment-add-on strategy: immunotherapy in combination versus standard chemotherapy-based regimens. Hazard ratio (HR) for overall survival (OS) and progression-free survival (PFS) were extracted and cumulated. Results: Seven trials (4278 patients) were included. The addition of immunotherapy to standard chemotherapy-based regimens significantly increased OS (HR 0.74; pÂ =Â 0.001) and PFS (HR 0.61; pÂ

KW - NSCLC

KW - PD-1

KW - PD-L1

KW - atezolizumab

KW - first line

KW - immunotherapy

KW - meta-analysis

KW - nivolumab

KW - pembrolizumab

U2 - 10.2217/imt-2018-0198

DO - 10.2217/imt-2018-0198

M3 - Articolo

VL - 11

SP - 921

EP - 930

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 10

ER -